anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
DIAGNOSIS AND TREATMENT OF VIRAL EFFECTS This invention provides methods of treatment and/or diagnosis and/or siting of viruses including the AIDS virus and others as well as the cells which they infect. The method comprises introducing near, into or onto the virus or the cell which the virus infects, or both, minute particles. These particles possess ferromagnetic, paramagnetic or diamagnetic properties. After being localized near, in or on the virus or the viral-infected cell, the particles are inductively heated by application of an alternating electromagnetic field. The inductive heating is continued for a period of time sufficient to bring about a temperature rise to a minimum necessary to kill the virus or cell or to desirably alter the behavior of the virus or infected cell. Prior to, during or after treatment, these particles can be used diagnostically to locate and/or map the virus in the living tissue.
Participants will receive Herceptin via IV infusion for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin IV will be given on Day 1 of each 21-day cycle, as 8 milligrams per kilogram (mg/kg) for a loading dose during Cycle 1 and as 6 mg/kg during subsequent cycles.
In the pursuit of mental and physical health, effective pain management stands as a cornerstone. Here, we examine a potential sex bias in pain management. Leveraging insights from psychological research showing that females' pain is stereotypically judged as less intense than males' pain, we hypothesize that there may be tangible differences in pain management decisions based on patients' sex. Our investigation spans emergency department (ED) datasets from two countries, including discharge notes of patients arriving with pain complaints (N = 21,851). Across these datasets, a consistent sex disparity emerges. Female patients are less likely to be prescribed pain-relief medications compared to males, and this disparity persists even after adjusting for patients' reported pain scores and numerous patient, physician, and ED variables. This disparity extends across medical practitioners, with both male and female physicians prescribing less pain-relief medications to females than to males. Additional analyses reveal that female patients' pain scores are 10% less likely to be recorded by nurses, and female patients spend an additional 30 min in the ED compared to male patients. A controlled experiment employing clinical vignettes reinforces our hypothesis, showing that nurses (N = 109) judge pain of female patients to be less intense than that of males. We argue that the findings reflect an undertreatment of female patients' pain. We discuss the troubling societal and medical implications of females' pain being overlooked and call for policy interventions to ensure equal pain treatment.
BACKGROUND: Neonatal jaundice (NNJ) affects a significant proportion of newborns globally, with an increased burden in low-resource settings. Effective health risk management of NNJ is hindered, particularly in resource-constrained environments, where early detection and treatment are challenging. The careSTART S1 Total Bilirubin Strip, a point-of-care testing (POCT) device based on a diazo-method, offers a potential solution by enabling onsite bilirubin measurement, thus, addressing the gap in early NNJ detection and management.
METHODS: The current study evaluated the analytical performance of the careSTART S1 Total Bilirubin Strip for precision, linearity, method comparison, and lot-to-lot consistency following CLSI guidelines. For method comparison, 105 residual EDTA whole blood samples were analyzed with the careSTART S1 Total Bilirubin Strip and compared with reference measurements from the Roche Cobas c702 analyzer. Additionally, statistical analyses, including Passing-Bablok regression and Bland-Altman plots, were performed.
RESULTS: The careSTART S1 Total Bilirubin Strip showed allowable (<10%) within-laboratory imprecision of 2.5%-3.6% across all levels and demonstrated linearity over the range of 4.16-439.3 μmol/L. Method comparison revealed a constant negative bias with a mean bias -4.19 μmol/L. However, the 95% confidence interval (-7.10 to -1.28 μmol/L) of the bias is covered by the prespecified allowable bias of 8.3%, at medical decision point. Lot-to-lot variation ranged from 0.14%-6.49%, and was within the acceptable critical difference of 8.3%.
CONCLUSION: The careSTART S1 Total Bilirubin Strip provided accurate and reliable bilirubin measurements that could contribute to neonatal care in settings lacking central laboratory facilities.
A whole melon worm vaccine and its preparation method are provided. The invention aims to solve the problem that ichthyophthiriasis damages fish species of salmon and trout. The whole-worm vaccine of the multi-seed melon is prepared by inoculating an insect liquid extracted from salmon and trout infected with the melon insect disease into carp serum for culture, filtering, diluting the final density of the insect liquid to 10000/mL, and crushing. The method comprises the following steps: 1. preparing an in vitro culture medium; 2. obtaining living multi-seed melon insects; 3. in-vitro expansion culture of the polygala tenuifolia; 4. harvesting the multi-seed melon insects; 5. and (5) preparing and storing the whole worm vaccine. The preparation method of the multi-seed melon worm whole-worm vaccine for preventing salmon and trout melon worm diseases is simple, has controllable conditions, can realize mass production, has good application effect, can achieve the immune protection rate of 78.67 percent, can effectively avoid huge breeding loss caused by the melon worm diseases, and has good market application prospect. The invention belongs to the field of salmon and trout multi-seed melon insect prevention and control.
Patients using Adapalene Cream, 0.1% should receive the following information and instructions:

1\. This medication is to be used only as directed by the physician.

2\. It is for external use only.

3\. Avoid contact with the eyes, lips, angles of the nose, and mucous membranes.

4\. Cleanse area with a mild or soapless cleanser before applying this medication.

5\. Moisturizers may be used if necessary; however, products containing alpha hydroxy or glycolic acids should be avoided.

6\. Exposure of the eye to this medication may result in reactions such as swelling, conjunctivitis, and eye irritation.

7\. This medication should not be applied to cuts, abrasions, eczematous or sunburned skin.

8\. Wax epilation should not be performed on treated skin due to the potential for skin erosions.

9\. During the early weeks of therapy, an apparent exacerbation of acne may occur. This is due to the action of this medication on previously unseen lesions and should not be considered a reason to discontinue therapy. Overall clinical benefit may be noticed after two weeks of therapy, but at least eight weeks are required to obtain consistent beneficial effects.
FIELD: medicine, phytotherapy. SUBSTANCE: agent normalizing motor system of bile-secretory ways and gastroenteric tract has swampy sweet flag roots with rhizomes and dandelion roots and, additionally, medicinal marsh-mallow roots and violet pensy (tricolor) herb in the following ratio of components, wt.-%: swampy sweet flag (roots with rhizomes), 5-15; dandelion (roots), 10-60; violet pensy (tricolor) (herb), 5-50 and medicinal marsh-mallow (roots), the balance. After addition of 15-25 wt.-% of field rest-harrow herb and 5-10 wt.-% of mint herb and/or fragrant dill to the agent composition the latter shows antihemorrhagic, anti-inflammatory agent, it improves kidney function and prevents venous congestion in abdominal cavity. Additional addition of the following herbs: milfoil herb or flowers, sandy common immortelle flowers (everlasting) in the amount 5-15 wt.-% to the agent composition the latter shows desensitizing, analgetic effect and stimulates production of pancreas enzymes. Additional addition of motherwort herb to the agent in the amount 5-10 wt.-% that acts as bitter principle and strong sedative results to the improvement of digestion, strong antiseptic effect, spasmolytic and analgetic effects. Agent is used as plant raw tincture prepared after extraction at 60-70 C for 1-2h. After intake the agent shows the improvement of the general state, normalization of intestine functions and bile-secretory ways, enzymatic function of pancreas, elimination of congestion symptoms in liver, skin cleansing and the enhancement of skin immunity. EFFECT: enhanced effectiveness of agent, valuable medicinal properties. 5 cl, 1 tbl
Increase in Blood Glucose: Niacin treatment can increase fasting blood glucose. In a simvastatin-controlled, 24-week study with SIMCOR the change from baseline in glycosylated hemoglobin levels was 0.2% for SIMCOR-treated patients and 0.2% for simvastatin-treated patients. Diabetic or potentially diabetic patients should be observed closely during treatment with SIMCOR, particularly during the first few months of therapy. Adjustment of diet and/or hypoglycemic therapy or discontinuation of SIMCOR may be necessary. 

Reduction in platelet count: Niacin can reduce platelet count. In a simvastatin-controlled, 24-week study with SIMCOR the mean percent change from baseline for patients treated with 2000/40 mg daily was -5.6%.

Increase in ProthrombinTime (PT): Niacin can cause small increases in PT . In a simvastatin-controlled, 24-week study with SIMCOR this effect was not seen. 

Increase in Uric Acid: Elevated uric acid levels have occurred with niacin therapy. In a simvastatin-controlled, 24-week study with SIMCOR this effect was not seen. Nevertheless, in patients predisposed to gout, SIMCOR therapy should be used with caution. 

Decrease in Phosphorus: Small dose-related reductions in phosphorous levels were seen in clinical studies with niacin. In a simvastatin-controlled, 24-week study with SIMCOR this effect was not seen.
The present invention relates to animal virology and epizootiology and genetic engineering technical field.Be specifically related to the Synthesis and application of a kind of highly pathogenic PRRSV (PRRSV) antigen multi-epitope gene.Highly pathogenic PRRSV WUH3 strain GP3, GP4, GP5, M is it is characterized in that to be connected by linker with the GP5B cell epitope of modification with the t cell epitope of N protein, and transform rear synthetic according to the preferences of Mammals to codon, is its nucleotide sequence as SEQ? ID? is protein sequence as SEQ shown in NO:1? ID? shown in NO:2.This multi-epitope gene of synthesis is included in eukaryon expression plasmid pcDNA3.1-mMEP, intestinal bacteria Escherichia containing this plasmid? coli? DH5 α/pcDNA3.1-mMEP is deposited in China typical culture collection center (CCTCC), does is preserving number CCTCC? NO:M? 2012171.The invention also discloses this gene preparing in porcine reproductive and respiratory syndrome DNA vaccination applies.
The aim of this clinical study was to evaluate the intensity and duration of postoperative pain after single-visit and multiple-visit root canal retreatment procedures. Patients who have asymptomatic failed endodontically treated teeth were included in this study and routine channel treatment procedure will be applied to these teeth. All of the patients have been recruited from the Istanbul Medipol University Dental Clinics in Istanbul. Eighty asymptomatic teeth were randomly participated into four treatment groups in terms of intracanal medicament applied. The presence of postoperative pain was assessed after 1, 6, 12, 24 and 48 hrs. Postoperative pain was recorded by each patient by using visual analogue pain scale. Before the retreatments, the nature of the study, complications and associated risks were totally explained and written informed consent was obtained from all study participants. The patients were offered local anesthetic before the treatment start. The routine root canal retreatment procedure was applied. Different intracanal medicaments used between sessions in accordance to the manufacturers' instructions. At the end of retreatment, each patient was given an evaluation sheet, explained the treatment procedure and using of visual analogue pain scales, and informed to be returned during the following one week. After one week the teeth was examined according to for pain intensity, percussion \& palpation sensitivity, swelling, analgesic intake and clinical status.
Obesity is associated with metabolic disorders such as dyslipidaemia, diabetes mellitus (DM), hypertension (HTN) and cardiovascular disease (CVD). There has been rising burden of childhood and adolescent obesity in most developing countries in recent years. Changes in dietary habits, junk and fast food, physical inactivity and smoking habits increases among adolescent students, which causes obesity and simultaneously increases risk of metabolic diseases. The objective of the study is to determine the correlation between Body Mass Index (BMI) and lipid profile among adolescent students of Bangladesh. This cross-sectional observational study was conducted among 79 undergraduate healthy adolescent students, aged 10-18 years who were selected through purposive sampling. The study was conducted from July 2022 to June 2023 in urban and rural areas of Dhaka, Narayanganj and Rangpur. Data was collected using a semi-structured questionnaire. Correlation of dyslipidemia and BMI was analyzed by Pearson Coefficient. Data was analyzed using SPSS version 22.0 with level of statistical significance at p<0.05. Mean age of the respondents was 14.9±4.5 years. Male and female ratio was 2.16:1. Among respondents, 46.8% had BMI 18.5-23.0 (normal), 31.6% had BMI 23.1-25.0 (overweight) and 21.5% had BMI >25.0 (obese). Prevalence of dyslipidaemia was 34.1%. Overweight and obese respondents had raised total cholesterol (TC) level 209.51±48.6 mg/dl and 218.36±80.0 mg/dl respectively. Mean high density lipoprotein (HDL) cholesterol level was 38.91±10.51 mg/dl in overweight and 36.54±10.04 mg/dl in obese. Mean low density lipoprotein (LDL) cholesterol level was 135.23±44.5 mg/dl in overweight and 143.61±56.0 mg/dl in obese. Among obese cases, 94.1% respondents had borderline triglyceride (TG) with mean 164.46±111.0 mg/dl. Among the study respondents, overweight and obesity (higher BMI) tend to have abnormal lipid profile. It is recommended that assessment of BMI should be incorporated into school health programme and those with overweight and obesity should be subjected to routine lipogram in order to apply timely preventive as well as therapeutic measures to save lives.
The invention relates to application of Lycojaponicumin C in the preparation of anti-human fungi drugs and belongs to the field of medicine. The Lycojaponicumin C has a very strong effect of inhibiting trichophyton rubrum, microsporum lanosum and trichophyton tonsurans. Therefore, the Lycojaponicumin C can serve as an anti-human fungus compound, and is expected to be applied to preparing relevant drugs. The application of the Lycojaponicumin C in the preparation of the anti-human fungi drugs is disclosed for the first time. The Lycojaponicumin C has the advantages that the skeleton type belongs to an unprecedented skeleton type, and the inhibitory activity on human fungi is unexpectedly high, so that the probability that other compounds give enlightenments does not exist. The Lycojaponicumin C has an outstanding substantial characteristic, and meanwhile makes remarkable progress in preventing human fungi infection.
Darbepoetin alfa is given to the patients. Target Hb level is 10.0g/dL and it should be maintained greater than or equal to 9.0g/dL and less than 11.0g/dL. If the Hb level exceeds 10.0g/dL in patients, reduce the dose amount or stop giving dose.
Patients will receive Maitland mobilizations along with hot pack and TENs and additional stretch of piriformis muscle is given. A total of 3 sessions would be conducted over a period of 1 week.
Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
<P>PROBLEM TO BE SOLVED: To provide a surface-treated powder that exhibits excellent adhesivity to skin and excellent effects for preventing color darkening, and a cosmetic having incorporated the same therewith that exhibits excellent adhesivity to skin and excellent effects for preventing color darkening.  <P>SOLUTION: The surface-treated powder comprises 100 pts.wt. of a powder usable as a cosmetic coated with 3-15 pts.wt. of a specific fluorine-modified acrylic polymer and with 1-5 pts.wt. of at least one compound selected from among a reactive organopolysiloxane, a polyolefin, a hydrogenated lecithin (including one in a salt form), an N-acylamino acid (including one in a salt form or a composition form), an acidic ester oil, a fatty acid (including one in a salt form), a dextrin fatty acid ester and a fructooligosaccharide fatty acid ester.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Subjects were secured on a standard ambulance stretcher, with a shear and pressure sensors attached to the body. Starting at 0 degrees head-of-bed (HOB) elevation, the ambulance traveled on a closed driver training course accelerating up to 30 mph and decelerating to a stop 5 times. Shear and pressure measurements were taken during the runs. The HOB was then elevated to 15 and 30 degrees respectively, and the procedure repeated. Subjects were asked to rate their comfort at each of the HOB elevations using a 0-10 scale. Following the first set of 15 runs, the course was repeated with the LiquiCell® ASMO.
Patients with complex congenital heart disease and single ventricle physiology typically undergo a staged surgical palliation to a situation where the single ventricle is recruited as the systemic pumping chamber and some (following a Glenn surgery) or all (following a Fontan surgery) systemic venous return flows passively to the lungs. While this physiology eliminates ventricular volume loading and normalizes systemic arterial oxygen saturations, there remain a number of physiologic burdens that limit functional capacity and life expectancy. Evidence suggests that this surgical imposition of the systemic and pulmonary vascular beds in series results in ventricular loading conditions that adversely affect ventricular function. At present, there exist limited means by which to mitigate these burdens, however, new therapies directed at reducing total pulmonary resistance may favorably affect patients with this physiology by reducing systemic venous pressures and improving both ventricular preload and afterload. One such therapy is inhaled nitric oxide (iNO), which is a selective pulmonary vasodilator that has been shown to reduce total pulmonary resistance and improve systemic venous pressures in this patient population. However limited data exist regarding the affects of pulmonary vasodilators like iNO on ventricular loading and ventricular-arterial coupling. This study proposes to assess the effects of pulmonary vasodilator therapy upon ventricular loading and ventricular-arterial coupling in single ventricle patients with passive pulmonary blood flow presenting for elective cardiac catheterization. The study components include obtaining routine (they would be obtained as a part of the clinically-indicated catheterization) hemodynamic measurements with hi-fidelity catheters rather than standard fluid-filled catheters, as well as simultaneous additional measurements with the same catheters at rest and during administration of iNO.
Experiment 1. High school athletes will complete a battery of tests including the Y-balance test, a version of the Star Excursion Balance Test (SEBT), a divided attention gait task, the Psychomotor Vigilance Task (PVT). The SEBT is an established, reliable outcome measure of dynamic postural stability through measurement of lower extremity reach distance. Our study will also utilize a force plate during SEBT testing to allow the investigators to sensitively measure center of mass in all planes. To test gait balance control and adaptation of gait strategy which have been shown to be impaired in concussed individuals acutely and chronically, athletes will walk at self-selected speed on the GAITRite® portable gait analysis walkway for three undivided attention trials and three divided attention trials during which a cognitive task, will be imposed.The GaitRite® will calculate spatio-temporal parameters during gait and has been used in the concussion literature. The PVT is a reliable and valid measurement of simple reaction time to an auditory cue. The outcome measure will be the mean reaction time. These tests were administered by licensed physical therapists, assisted by students from both the Doctorate of Physical Therapy (DPT) and PhD physical therapy programs at UCA, before the initiation of summer 2016 football practices for all athletes in the program. The total testing time per athlete will not exceed 1.5 hours. The battery will be administered again to all athletes in the football program after the season has ended and prior to the end of the school year in the spring 2017. The 2017-2019 season will test both football and soccer (male and female athletes) and will include functional testing for athletes who have had a concussion through concussion clinic.

Experiment 2. Qualified athletic trainers or Physical Therapists, with oversight by Dr. Israel, will administer the ImPACT using the same schedule as described in Experiment 1. The ImPACT is a widely used neurocognitive testing component of the standard three-prong approach to concussion management which also includes symptom inventories and static balance assessment. The computerized test evaluates concentration, attention, memory, visual motor speed, and reaction time. High sensitivity and specificity for concussion using the ImPACT has been shown. The test also has been shown to be a valid and reliable measure in the high school and collegiate populations. Composite scores for each of the non-injured athletes will be stratified by age to examine changes across the three assessments. Hunt and Ferrara have shown significant change in baseline assessments between 9th grade and 11th and 12th grade age groups driven by 9th grade test scores indicating that biennial testing for young adolescents may not be sufficient.The current recommendation for this younger age group is annual testing, though recent studies call for the investigation of even more frequent testing, thus our plan to test at six months. ImPACT testing will not exceed 1 hour. The 2017-2018 season will test both football and soccer (male and female athletes) for ImPACT testing.
PCT No. PCT/JP85/00715 Sec. 371 Date Oct. 10, 1986 Sec. 102(e) Date Oct. 10, 1986 PCT Filed Dec. 26, 1985 PCT Pub. No. WO86/04067 PCT Pub. Date Jul. 17, 1986.A method of purifying a polypeptide having a physiological activity such as one having interferon activities from a culture mixture of a microorganism obtained by a recombinant DNA technique and capable of producing the polypeptide is disclosed. The method comprises subjecting the cultured cells to extraction and purification in the presence of a salt of zinc or copper and polyethyleneimine thereby inhibiting decomposition and denaturation of the polypeptide. The extracted polypeptide can be further purified by column chromatographies using a column containing an anion exchange resin, column containing a cation exchange resin and column containing a gel filtration resin.